Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 6 |
Immune System Diseases | 3 |
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
AAV based gene therapy | 2 |
Recombinant coagulation factor | 2 |
Immunoglobulin | 2 |
Blood components | 2 |
Target |
Mechanism factor IX stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Nov 2022 |
Target |
Mechanism C1-INH modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Jun 2017 |
Target |
Mechanism F8 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 May 2016 |
Start Date15 Feb 2017 |
Sponsor / Collaborator |
Start Date10 Dec 2007 |
Sponsor / Collaborator |
Start Date11 Jul 2007 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Normal Human Immunoglobulin (CSL Behring) | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating More | Approved |
Lonoctocog alfa ( F8 ) | Hemophilia A More | Approved |
Albumin (Human)(CSL Behring) | Hypoalbuminemia More | Approved |
Albutrepenonacog alfa ( F10 ) | Hemorrhage More | Approved |
Rho(D) Immune Globulin Intravenous (Human)(CSL Behring) | Purpura, Thrombocytopenic, Idiopathic More | Approved |